Curis Lifesciences Limited
Bookbuilding IPO · NSE
- Price band
- ₹120 - ₹128
- Lot size
- 1,000 shares
- Issue amount
- ₹27.52 cr
- Total subscription
- 74.47×
- Opens
- 7 Nov 2025
- Closes
- 11 Nov 2025
- Allotment
- 12 Nov 2025
- Listing
- 14 Nov 2025
Offer at a glance
Issue overview
- Issue size
- 21,50,000 shares
- Face value
- ₹10 per share
- Minimum investment
- ₹1,20,000
- Fresh issue
- ₹27.52 cr
- Offer for sale
- ₹0 cr
- Registrar
- Link Intime India Private Limited
- Listing exchange
- NSE
- Maximum investment
- ₹1,28,000
- Issue type
- Bookbuilding IPO
- Shares before issue
- 59,34,434
- Shares after issue
- 80,84,434
Lot sizes
| Category | Lots | Shares | Amount |
|---|---|---|---|
| RETAIL | 2 | 2,000 | ₹2,56,000 |
| sHNI | 3 | 3,000 | ₹3,84,000 |
| bHNI | 8 | 8,000 | ₹10,24,000 |
Share reservation
Subscription & GMP
Subscription by category
Reported 11 Nov 2025
GMP history
Day-wise demand
Application-wise demand
| Category | Reserved applications | Applied applications |
|---|---|---|
| QIB | 0 | 44 |
| NIB | 0 | 5,576 |
| RETAIL | 358 | 15,853 |
| HNIs(10L +) | 69 | 3,605 |
| HNIs (2-10L) | 34 | 1,971 |
Subscription demand
Amounts in ₹ crore. HNI subcategories are included in the NII total.
| Category | Offered | Demand |
|---|---|---|
| QIBs | 5.24 | 503.49 |
| FIIs | 0 | 187.28 |
| FIs | 0 | 10.34 |
| Others | 0 | 305.87 |
| RETAIL | 9.16 | 405.84 |
| NIB | 3.94 | 456.59 |
| HNIs 2+ | 1.31 | 78.84 |
| HNIs 10+ | 2.64 | 377.75 |
Financial performance
Company financials
In Crores · Reported periods may include interim results.
Key performance indicators
| Metric | Jul-25 | Mar-25 | Mar-24 | Mar-23 |
|---|---|---|---|---|
| EPS | 0 | 0 | 0 | 0 |
| ROE | 16.26 | 55.25 | 141.51 | 2,752.56 |
| ROCE | 11.65 | 27.83 | 33.57 | 14.83 |
| RONW | 0 | 0 | 0 | 0 |
| PRE IPO(PE) | 0 | 12.44 | 0 | 0 |
| POST IPO(PE) | 12.01 | 0 | 0 | 0 |
Values and labels as reported in the issue data.
Peer comparison
| Company | P/E(X) | CMP* (₹) | Face value (₹) | NAV/Share (₹) | RONW(%) | EPS (Basic) (₹) |
|---|---|---|---|---|---|---|
| Curis Lifesciences Limited | 0 | 0 | 0 | 27.34 | 37.62 | 10.29 |
| Sotac Pharmaceuticals Limited | 18.30 | 0 | 0 | 47.99 | 9.00 | 4.32 |
| Lincoln Pharmaceuticals Limited | 12.21 | 0 | 0 | 335.34 | 12.27 | 41.11 |
Company information
Company profile
Curis Lifesciences Limited, founded in 2010, is a pharmaceutical company engaged in developing, manufacturing, and distributing a wide range of medicines. It produces pharmaceutical products for both domestic and global markets through loan license, contract manufacturing, and its own brand marketing. The company serves over 100 corporate clients under contract manufacturing and two clients for its own brands in Yemen and Kenya. Its product range includes tablets, capsules, oral liquids, external preparations, and sterile ophthalmic ointments. The company operates a modern manufacturing facility in Sanand, Gujarat, maintaining strict quality standards, and as of July 31, 2025, it employs 95 permanent staff.
Strengths
- Experienced Leadership and Skilled Management: Promoters with 13–15 years of experience in the pharmaceutical sector and medical expertise lead the company, ensuring informed strategic decisions, operational efficiency, and sustained client trust.
- Broad and Diverse Product Range: Offers an extensive portfolio including tablets, capsules, oral liquids, external applications, and sterile ophthalmic ointments, supported by valid manufacturing licenses (G/25/2225 and G/28/1632).
- WHO-GMP Certified Facility with Global Reach: The Sanand, Gujarat-based manufacturing unit is WHO-GMP certified, strategically located for logistics and skilled workforce access, and holds international product registrations in markets such as Yemen, Kenya, the Philippines, and Nigeria.
Risk factors
- Operational Concentration Risk: Heavy reliance on a single manufacturing facility in Sanand, Ahmedabad (Gujarat) exposes the company to regional, environmental, and regulatory risks that could disrupt operations and impact financial performance.
- Regulatory and Approval Challenges: As part of a highly regulated sector, delays or lapses in obtaining or renewing statutory licenses, certifications, or product approvals may hinder business continuity and affect profitability.
- Debt Servicing and Compliance Risk: Previous delays in loan repayments pose potential reputational and financial risks; continued focus on disciplined financial management is crucial to maintain lender confidence and credit health.
Promoters
Mr. Dharmesh Dashrathbhai Patel
Mr. Siddhant Jayantibhai Pawasia
Mr. Piyush Gordhanbhai Antala
Mr. Jaimik Mansukhbhai Patel
Registrar & documents
Lead manager
Finaax Capital Advisors Private Limited
Registrar & contacts
Link Intime India Private Limited
[email protected]Official registrar portal ↗IPO allotment status guide →Registered office
PF-23, GIDC Sanand - II, Industrial Estate, Sanand Ahmedabad, Gujarat, 382110
+91 99045 22543
[email protected]Company website ↗Understanding CURIS IPO data
Compare the price band and required investment with the company profile, financial results and offer documents. Subscription figures show reported demand by category; they do not establish the value of the business. GMP is an unofficial indication and can change before listing.